Introduction
The drug efflux transporter P-glycoprotein is the product of the ABCB1/MDR1
gene. Drug transporting P-glycoprotein is a critical part of the blood brain barrier (BBB) and essential in preventing the blood to brain penetration of substrates (Schinkel et al., 1995) . However, BBB Pgp also prevents brain delivery of CNS acting drugs including those for brain tumor treatment.
Cranial BBB Pgp is regulated by a number of signaling pathways. In mice the pregnane X receptor (PXR) mediates induction of BBB Pgp by a variety of ligands including the prototypical mouse PXR agonist pregnenolone 16α-carbonitrile (PCN) ).
The glucocorticoid receptor has been shown to mediate dexamethasone induction of rodent BBB Pgp (Narang et al., 2008) . Activators of the constitutive androstane receptor (CAR), including 1,4-Bis[2(3,5-dichloropyridyloxy)]benezene (TCPOBOP) and phenobarbital induced Pgp protein and function in rat and mouse brain capillaries ex vivo (Wang et al., 2010) . Spinal BBB Pgp is regulated by activators of the Aryl hydrocarbon receptor (AhR) and Nrf2 (Wang et al., 2014) .
The human MDR1 promoter contains PXR and CAR regulatory sequences at about -8 kb (Geick et al., 2001) , and human MDR1 transcription can be induced in human liver and intestinal cell models by prototypical PXR and CAR activators (Schuetz et al., 1996a ) (Hartley et al., 2004) . However, data on regulation of human BBB MDR1 in vivo is lacking, despite the fact that there are numerous reasons to understand and predict how MDR1 is regulated at the human BBB in vivo (Miller, 2010) . The most extensively described immortalized human BBB cells (hCMEC/D3) (Weksler et al., 2013) (Bauer et al., 2004) , and mice humanized with hPXR can similarly regulate mouse BBB Pgp (Miller et al., 2008) . However, these models cannot predict the potential of the human MDR1 5'-regulatory sequences to respond to these same regulators in the brain in
vivo.
A mouse mdr1a-luc model has previously been generated in which the luciferase reporter was inserted into the genomic locus of the mouse mdr1a gene by homologous recombination (Gu et al., 2009) (Gu et al., 2013) Creation of MDR1-luc transgenic mice. The human MDR1-luciferase plasmid was generated by amplifying the human MDR1 promoter (-9,912/+180, relative to the transcription initiation site) and ligating it into the KpnI/SmaI site of pGL3Basic (Promega, Madison, WI) as described (Schuetz et al., 2002) . The transgene was linearized by restriction enzyme digestion and the purified fragment was microinjected into single cell-stage FVB embryos and implanted into pseudo-pregnant mice.
MDR1-luc genotyping. Genomic DNA was isolated from mouse tails using the DNeasy Blood and Tissue Kit (Qiagen, Valencia, CA). Two methods were used to determine the presence or absence of luciferase in genomic DNA. Luciferase (255 bp fragment) was PCR amplified using primers lucS (TTCGCAGCCTACCGTGGTGTT) and lucAS
followed by 32 cycles of denaturation (94°C for 20s), annealing (55°C for 20s), and synthesis (65°C for 30s), and a final synthesis (65°C for 1min). The amplicon was visualized on a 2% agarose gel. Alternatively, mice were genotyped using real time PCR with specific probes designed to detect luciferase (Transnetyx, Cordova, TN). Insertion of the entire MDR1
promoter was confirmed by PCR amplification using genomic DNA from MDR1-luc mice and eight sets of human MDR1 specific primers that specifically amplified regions between -9447 bp to +180bp of the human MDR1 promoter transgene.
Multiplex ligation-dependent probe assay (MLPA) to genotype zygosity of MDR1-luc transgene alleles. Since the exact insertion site of the MDR1-luc transgene was not known, MLPA was used to genotype transgene zygosity. During MLPA, an oligonucleotide ligation reaction was performed, followed by PCR using fluoresceinconjugated primer, such that the amount of PCR product generated for each genomic sequence is directly proportional to the number of input copies. The mice bearing Luc transgene alleles were analyzed by designing our own MLPA Luc probe set to have an amplification product of size 140 bp. Three control probes elsewhere in the mouse genome were used, with amplification products ranging in size from 108bp, 114bp and 136 bp (Kozlowski et al., 2007) . Each probe set was composed of a 5' and a 3' halfprobe, each containing unique target specific sequence, stuffer sequence, and universal primer sequences on their 5' and 3' ends, (Kozlowski et al., 2007 product length of 140bp. Control probe sets were used exactly as indicated (Kozlowski et al., 2007) . The probe set consists of a 5' half-probe and a 3' half-probe. Each probe contains universal primer sequence, stuffer sequence, and target sequence, the latter of which is specific for the transgene being assessed. Total length of PCR product assessed by capillary electrophoresis is shown by the total product length. Primers used for PCR: heterochromatic-euchromatic boundary and the telomere of the specifically hybridizing chromosome. The MDR1-luc mice were found to have a transgene insertion that is 10% of the distance from the heterochromatic-euchromatic boundary to the telomere of chromosome 3, an area that corresponds to band 3A to 3B.
In Vivo bioluminescent imaging of MDR1-luc reporter mice. Mice were anesthetized by isoflurane gas (2%, inhalation) and given an i. Ex Vivo imaging of bioluminescence in brain slices from MDR1-luc transgenic mice.
After in vivo imaging, mice were immediately sacrificed under anesthesia by carbon dioxide gas following cervical dislocation. Whole brain was immediately dissected out of the skull and dorsal and ventral of brain image were taken. The brain was immobilized on a brain slicer matrix (Zivic Instruments, Pittsburgh, PA) and coronally sliced into 2mm
thickness. The brain slices were placed into individual wells of a 12 well plate. Dluciferin was directly re-applied on each brain slice and coronal image was taken from both sides of the slices. Dorsal, ventral, sagittal and coronal images were scaled to maximum intensity of 1 x 10 5 photons (p)/s/cm 2 /sr while microdissected brain images were scaled to maximum intensity of 3.5 x 10 4 photons (p)/s/cm 2 /sr.
Quantitation of fluroescently immunostained mouse Pgp and CD31 in coronal brain
slices. MDR1-luc adult mice were perfused with cold PBS and 4% paraformaldehyde (PFA), the brains were removed and processed for paraffin embedding. Embedded tissue was cut at 4µm thickness. Slides were deparaffinized and antigens retrieved with Target Retrieval solution pH 6.0 (Dako #S1699, Carpinteria, California) in a pressure cooker for 15 minutes. After retrieval, slides were rinsed, treated with 3% hydrogen peroxide, and blocked with 3% Normal Donkey serum (Jackson ImmunoResearch #017-000-121, West
Grove, PA) in Phosphate Buffered Saline with 0.3% Triton X-100 (PBST). Slides were incubated with purified rabbit anti-Pgp antibody (1:50,000) (raised to a peptide containing amino acids 555-575 of human Pgp and prepared by Dr. John Schuetz) and goat anti CD31 IgG (1:300) (R&D Systems #AF3628, Minneapolis, MN) for 1 hr.
Stained slides were rinsed three times in PBST and then incubated with Alexa donkey This article has not been copyedited and formatted. The final version may differ from this version. Imaging was performed on a widefield Nikon TE2000S microscope equipped with a 20X 0.75NA Plan Apo lens and a Photometrics Coolsnap K4 camera. Fluorescent images were captured by using 3 X 3 binning and cropping to the center of the chip, resulting in individual images that were 512 x 512 pixels. Images were captured as montages and were typically comprised of 1000-1300 images. Quantitation was performed using NIS Elements software. Each channel was thresholded to distinguish signal above background and mean intensities for each thresholded channel were calculated. In total 18 measurements of 39,992 µm 2 size (the region of interest, ROI)
were randomly selected per region and taken for both frontal cortex and cerebellum.
Numerical values were determined for binary area (total area of pixels that show any intensity within the threshold for the ROI (and this could be bright or dim)); Binary sum (total intensity within the set threshold); and, Binary mean intensity (sum intensity/binary area). To determine differences in vessel density in each region, the binary area for CD31 in the frontal cortex vs. cerebellum was compared. To determine the expression of Pgp per brain capillary in each region we calculated the mean Pgp intensity/mean CD31 intensity for the frontal cortex vs. cerebellum.
All statistical calculations were performed using statistical program R: A Results MDR1-luc transgenic mice. We developed MDR1-luc mouse lines containing ~10 kb of 5'-flanking human MDR1 sequence directing expression of luciferase (Fig 1A) . After zygote microinjection and implantation, we identified multiple founder lines based on PCR screening and mouse tail luminescence. Two founder lines showed luciferase expression in brain and spine and one of these transgenic lines was selected for this study.
We performed fluorescence in situ hybridization (FISH) analysis of MDR1-luc in heterozygous transgenic mice. The MDR1-luc mice had insertion of the transgene at a single location on chromosome 3 (Fig 1B) and it was observed in all metaphase spreads examined from this line. PCR analysis of genomic DNA from the transgenic line with primers covering 9766 bp of the human MDR1 promoter confirmed that the entire promoter had inserted into the mouse genome.
MDR1-luc is inducible in the head and spine of reporter mice by activators of CAR,
PXR and GCR and the Bcrp/Abcg2 inhibitor, elacridar, further increases brain bioluminescence. In vivo dorsal and ventral imaging of transgenic mice showed that the highest basal level of luciferase activity was in the head region and in some mice along the spine (Fig 2) . The MDR1-luc construct contains the regulatory cluster of nuclear response elements (-7864 to -7817bp relative to the transcription start site of the human MDR1 gene) (Geick et al., 2001) . Since P-glycoprotein is induced at the blood brain barrier by CAR activators (Bauer et al., 2004) , mice were treated with the potent CAR This article has not been copyedited and formatted. The final version may differ from this version. agonist TCPOBOP (Tzameli et al., 2000) . Relative to baseline luciferase activity, there was a time-dependent induction of luminescence in the brain and spine. This pattern demonstrated that the human MDR1 5'-flanking sequence was sufficient to direct CNS expression of the luciferase reporter.
We next tested whether human MDR1 transcription was induced by other drugs demonstrated to increase Pgp in the brains of mice in vivo (Bauer et al., 2004 ) (Narang et al., 2008) . Treatment with phenobarbital (CAR activator) and dexamethasone
(glucocorticoid receptor & PXR activator), each increased MDR1-LUC transcription in
brains of the transgenic mice (Fig 3) . Since D-luciferin is a substrate of Bcrp (Zhang et al., 2007 ), a transporter that can limit brain availability of D-luciferin at the blood brain barrier (Bakhsheshian et al., 2013) , we treated mice with an oral dose of elacridar (100 mg/kg) for four hours to maximize the brain to plasma concentration (Sane et al., 2012) .
Elacridar increased the total MDR1-luc bioluminescent signal up to two-fold in vehicle and drug treated mice (Fig 4) , but did not change the regional pattern of MDR1-luc expression in the brain and spine of any mice. Elacridar's effect appears to be due to inhibition of Bcrp, and not induction of Pgp, because four hour treatment with elacridar failed to activate PXR and increase Pgp in an in vitro test system (E. Schuetz unpublished observation).
Brain localization of the human MDR1-luc signal versus mouse P-glycoprotein by

IHC.
Brains from the MDR1-luc mice imaged in vivo were excised and imaged dorsally, ventrally, sagitally (Fig 4) and in serial coronal slices (Fig 5) was unique in the MDR1-luc model compared with other transgenic reporter mice such as androgen receptor element (ARE)-luc mice (Dart et al., 2013) , or estrogen receptor element (ERE)-luc mice (Stell A et al., 2008) , or tyrosine hydroxylase promoter-luc mice (Dodd KW et al., 2011) . While the intensity of MDR1 transcription increased with various inducers, the distribution pattern of luciferase signal throughout the brain was similar, regardless of inducer. All chemicals increased MDR1 transcription to a greater extent in the cortex compared to the cerebellum. The coronal slices were further dissected and luciferase signal was higher in the cortex vs. cerebellum and was expressed in the white matter, thalamus, striatum, hippocampus, substantia nigra, brain stem and internal capsule (Fig 6) .
Brain tissue was processed for colorimetric immunohistochemistry using an antiluciferase antibody. The luciferase signal was localized to the BBB of vehicle treated MDR1-luc mice, and was induced in the endothelial cells of capillaries of phenobarbital treated MDR1-luc mice (Fig 7) .
To determine whether mouse Pgp showed a similar regional pattern of brain expression in these same mice, MDR1-luc brain tissue was processed by fluorescent immunohistochemistry using anti-Pgp and anti-CD31 (a vessel endothelial specific marker) antibodies and the fluorescent signal intensity was quantified. Consistent with the regional variation in MDR1-luc transcription, the mean mouse BBB Pgp signal, normalized to CD31 signal, was higher in the frontal cortex compared to the cerebellum (Fig 8) (Otsuka et al., 1991) (Zhao and Pollack, 2009 ). Thus, the regional differences in MDR1-luc reporter activity documented by photon imaging appear to mirror regional differences reported in blood flow, capillary density and Pgp expression (Fig 8) .
This article has not been copyedited and formatted. The final version may differ from this version. luminescence suggesting BBB Bcrp still limits some D-luciferin brain penetration, even at the high doses used here.
Our data shows that the MDR1-luc signal was not uniformly distributed in mouse brain and was consistently higher in the cortex vs. cerebellum in both untreated and treated mice. In addition, quantitative immunohistochemistry analysis found the mean Pgp expression in mouse brain was significantly higher in cortex compared to cerebellum (Fig 8) . These results are consistent with several lines of evidence that Pgp activity shows regional distribution in the brain. First, Zhao and Pollack (Zhao and Pollack, 2009 ) previously performed in situ brain perfusion of Pgp substrates in Pgp WT and KO mice and found that the rate of regional perfusion flow and Pgp efflux activity was directly proportional to local capillary density in mouse brain. For example, pons, medulla and cerebellum had the lowest vascular volume and functional flow rate, lowest blood perfusion flow rate, and lowest Pgp efflux ratio. Conversely, colliculi, thalamus and parietal cortex had the highest vascular volume and functional flow rate and the highest Pgp efflux ratio. Secondly, some animal studies with PET imaging have reported that Pgp inhibition increases substrate penetration to the greatest extent in the cerebellum (Zoghbi et al., 2008) and least in the frontal cortex. This result is interpreted to mean that Pgp function is lower in cerebellum vs. cortex and this results in a greater effect of the Pgp inhibitor on Pgp function in the cerebellum vs. the cortex. Hence, the regionality of MDR1-luc expression is consistent with literature reports on regionality in Pgp-mediated efflux, and also has potential pharmacological implications, for example, since opioid receptors (targets of Pgp opioid substrates) are also concentrated in the thalamus and cortex regions (Inturrisi, 2002) .
This article has not been copyedited and formatted. The final version may differ from this version. chemical entity is based not on direct evaluation of whether a drug induces Pgp, but on whether it induces CYP3A (Zhang et al., 2009) . If the drug is a CYP3A inducer, then further testing for Pgp induction in vivo is warranted. However, this advice is complicated by examples of tissue and species differences in induction of CYP3A and MDR1 (Schuetz et al., 1996a ) (Hartley et al., 2004) . Moreover, the human BBB cells culture model has lost MDR1 regulation (Dauchy et al., 2009 ). In addition, it is desirable to determine if induction of Pgp actually occurs in the brain in vivo because of the added complication that the inducer has to effectively penetrate the BBB drug transport barrier.
Indeed, rifampin, phenobarbital and dexamethasone are all reported Pgp substrates (Schuetz et al., 1996b )(Luna-Tortos et al., 2008 ) (Schinkel et al., 1995) . Nevertheless, at the drug exposure levels used in these studies, each of these drugs was clearly able to sufficiently penetrate the brain endothelial cells to induce MDR1. Hence, an in vivo model was clearly needed for further assessment of MDR1 regulation in the brain in vivo.
It is important to understand regulation of MDR1 because basic mechanistic understanding of how brain Pgp is regulated by drugs, inflammation and oxidative stress and in disease states is lacking (Miller, 2010) . Ex vivo analysis of Pgp in rodent brain tissue found that BBB Pgp is induced by seizures (van Vliet et al., 2007) , and in amyotrophic lateral sclerosis (Jablonski et al., 2012) , and that phenobarbital induced Pgp only in the hippocampus of epileptic rats (van Vliet et al., 2007) Alzheimer's disease. It was previously shown that Pgp could efflux amyloid beta (Aβ)
peptide from the brain (Cirrito et al., 2005) , and hence, that modulation of Pgp activity might directly influence progression of Aβ pathology. Our results demonstrate that brain Pgp can be induced by a variety of drugs including rifampin which, intriguingly, has previously been shown to slow the decline of patients with mild to moderate Alzheimer's (Loeb et al., 2004) , potentially through induction of MDR1.
MDR1-luc mice might be of value to identify chemicals that down-regulate
MDR1 transcription at the BBB and enhance brain exposure of Pgp substrates.
Attempts to block BBB Pgp and enhance drug brain delivery have been largely unsuccessful, making different approaches, such as modulating Pgp expression, important alternative strategies (Miller, 2010) . Indeed there has been limited success in inhibiting BBB Pgp efflux in humans, primarily due to the inability to achieve unbound systemic inhibitor concentrations sufficient to elicit appreciable inhibition (Kalvass et al., 2013) .
Although not tested in this study, one alternative approach would be to screen chemical libraries to identify chemicals capable of down regulating MDR-luc transcription in vitro;
in theory, these chemicals could be rapidly evaluated for their potential to regulate expression of brain MDR1-luc in whole animals.
The application of this MDR1-luc model to predict regulation of human Pgp still has challenges including species differences in the interaction of compounds with mouse vs. human PXR, and in pathways of metabolism or BBB transport of drugs.
However, interbreeding the MDR1-luc model with mice humanized for nuclear hormone receptors, CYPs or drug transporters (Scheer & Wolf, 2013) (Scheer & Wolf, 2014) would potentially improve the utility and predictability of this in vivo model. 
